Enlivex Increases Previously Announced Bought Deal Offering to Approximately $46.0 Million of Ordinary Shares
09 févr. 2021 23h25 HE
|
Enlivex Therapeutics Ltd
Nes Ziona, Israel, Feb. 09, 2021 (GLOBE NEWSWIRE) -- Enlivex Therapeutics Ltd. (NASDAQ: ENLV), a clinical-stage macrophage reprogramming immunotherapy company targeting diseased macrophages in...
Enlivex Announces $10 Million Bought Deal Offering of Ordinary Shares
09 févr. 2021 17h25 HE
|
Enlivex Therapeutics Ltd
Nes Ziona, Israel, Feb. 09, 2021 (GLOBE NEWSWIRE) -- Enlivex Therapeutics Ltd. (NASDAQ: ENLV), a clinical-stage macrophage reprogramming immunotherapy company targeting diseased macrophages in...
Enlivex Reports Positive Top-Line Results from Phase II Clinical Trial Evaluating Allocetra in Severe and Critical COVID-19 Patients and Provides a Program Update
03 févr. 2021 07h55 HE
|
Enlivex Therapeutics Ltd
Phase II (16 patients treated, 9/16 (56%) with severe illness, 7/16 (44%) with critical illness, follow-up period of 28 days post-AllocetraTM treatment) 0/16 (0%) mortality on day-28 ...
Enlivex to Present at the H.C. Wainwright BioConnect 2021 Virtual Conference
11 janv. 2021 08h00 HE
|
Enlivex Therapeutics Ltd
Nes Ziona, Israel, Jan. 11, 2021 (GLOBE NEWSWIRE) -- Enlivex Therapeutics Ltd. (Nasdaq: ENLV, the “Company”), a clinical-stage macrophage reprogramming immunotherapy company, today announced that...
Enlivex Announces Pre-Print Publication of Full Results from Phase Ib Severe Sepsis Trial on medRxiv
21 déc. 2020 08h00 HE
|
Enlivex Therapeutics Ltd
– Comparison of 10 AllocetraTM-treated patients with 37 matched controls showed significant positive responses in state of organ failure, duration of ICU stay and mortality in a highly fragile and...
Enlivex Announces Issuance of New Chinese Patent Covering Allocetra Immunotherapy
07 déc. 2020 08h00 HE
|
Enlivex Therapeutics Ltd
Nes Ziona, Israel, Dec. 07, 2020 (GLOBE NEWSWIRE) -- Enlivex Therapeutics Ltd. (Nasdaq: ENLV, the “Company”), a clinical-stage immunotherapy company, today announced that the China National...
Enlivex Reports Positive Interim Results From Phase II Clinical Trial Evaluating Allocetra in Severe and Critical COVID-19 Patients
03 déc. 2020 08h00 HE
|
Enlivex Therapeutics Ltd
Nes Ziona, Israel, Dec. 03, 2020 (GLOBE NEWSWIRE) -- Enlivex Therapeutics Ltd. (Nasdaq: ENLV, the “Company”), a clinical-stage immunotherapy company, today reported positive interim results of an...
Enlivex Reports Positive Two-Year Clinical Outcome For A Hospitalized Patient with Erosive Osteoarthritis Treated with Allocetra
18 nov. 2020 08h00 HE
|
Enlivex Therapeutics Ltd
* Significant short and long-term clinical improvement for a hospitalized patient with a rare disease that currently has no effective treatment options * Nes Ziona, Israel, Nov. 18, 2020 (GLOBE...
Enlivex Appoints Former ArQule, Inc. Executive Dr. Brian Schwartz to the Company’s Board of Directors
17 nov. 2020 08h18 HE
|
Enlivex Therapeutics Ltd
* Dr. Schwartz Served as ArQule’s Chief Medical Officer and Head of Research and Development Prior to the $2.7 billion Acquisition of ArQule by Merck in February 2020 * Nes Ziona, Israel, Nov. ...
Enlivex to Present Schedule for Sepsis, COVID-19 and Solid Cancer Programs at H.C. Wainwright’s 6th Annual Israel Conference
11 nov. 2020 08h14 HE
|
Enlivex Therapeutics Ltd
Nes Ziona, Israel, Nov. 11, 2020 (GLOBE NEWSWIRE) -- Enlivex Therapeutics Ltd. (Nasdaq: ENLV, the “Company”), a clinical-stage immunotherapy company, today announced that it will present the...